Asset Details
Do you wish to reserve the book?
Catecholaminergic polymorphic ventricular tachycardia in children—incidence and trends in detection, presentation and management
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Catecholaminergic polymorphic ventricular tachycardia in children—incidence and trends in detection, presentation and management
Do you wish to request the book?
Catecholaminergic polymorphic ventricular tachycardia in children—incidence and trends in detection, presentation and management
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Catecholaminergic polymorphic ventricular tachycardia in children—incidence and trends in detection, presentation and management
2025
Overview
ObjectiveTo establish a birth rate for catecholaminergic polymorphic ventricular tachycardia (CPVT) diagnosed in childhood and observe trends in presentation and management.DesignRetrospective cohort study.SettingThe Inherited Arrhythmia Clinic at The Sydney Children’s Hospitals Network, a paediatric tertiary referral network, New South Wales (NSW), Australia (2002–2021), where there are 86 000–97 000 live births/year.PatientsChildren diagnosed with CPVT aged 0–16 years.InterventionsClinical data were extracted and evaluated for trends. Using birth year data, the birth rate of CPVT detected in childhood was calculated.Main outcome measuresBirth rate of CPVT detected in childhood in NSW (with post hoc comparison to New Zealand), trends in diagnosis and management, and outcome at last follow-up.Results32 children in NSW were diagnosed with CPVT between 2002 and 2021 (0–16 years, median 9 years, 14 (54%) female). Of these, 28 (88%) presented with symptoms (cardiac arrest 20/32, 62.5%) and four (12%) were identified through family screening. Relevant genetic variants were identified in 25/31 (78%). During follow-up (median 4.5 years), symptomatic cardiac events (death n=1) occurred in 10 (33%), largely related to suboptimal adherence or monotherapy beta blocker. In NSW, CPVT was diagnosed during childhood following 1 in 65 000 live births (95% CI 1 in 91 000 to 1 in 46 000). In New Zealand, the corresponding figure was 1 in 84 000 live births (95% CI 1 in 138 000 to 1 in 52 000).ConclusionsThe rate of infants born who are later diagnosed with CPVT in childhood is approximately 1 in 65 000 live births. Suboptimal adherence and beta blocker therapy without flecainide appeared related to recurrent cardiac events.
